Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

1.400 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chromadex Corp CS

< Previous 1 2 3 4 Next >
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
From ChromaDex Corporation
Via Business Wire
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
From ChromaDex Corporation
Via Business Wire
Recap: ChromaDex Q4 Earnings
ChromaDex (NASDAQ:CDXC) reported its Q4 earnings results on Wednesday, March 9, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex... 
Via Benzinga
Recap: ChromaDex Q3 Earnings
ChromaDex (NASDAQ:CDXC) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:02 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022
From ChromaDex Corporation
Via Business Wire
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinamide Riboside
From ChromaDex Corporation
Via Business Wire
ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements
ChromaDex Corp (NASDAQ:CDXC) has 
Via Benzinga
ChromaDex and Designs for Health Partner for New Product Development on Niagen®
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation (CDXC) Q3 2021 Earnings Call Transcript
CDXC earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ChromaDex Corporation Reports Third Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021
From ChromaDex Corporation
Via Business Wire
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth
From ChromaDex Corporation
Via Business Wire
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
From ChromaDex Corporation.
Via Business Wire
Why ChromaDex Stock Is Sinking Today
The company lost a key patent infringement lawsuit but plans to appeal the court decision. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Why Are ChromaDex Shares Trading Lower On Wednesday?
ChromaDex Corp (NASDAQ: CDXC) dropped over 20% during the premarket despite its announcement over plans to appeal a court ruling issued by the U.S. District Court... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) shares increased by 68.88% to $11.94 during Wednesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit
From ChromaDex Corporation
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers IVERIC bio (NASDAQ:ISEE) stock increased by 65.36% to $14.37 during Friday's pre-market session. The company's market cap stands at $1.4 billion. T2... 
Via Benzinga
ChromaDex Corporation (CDXC) Q2 2021 Earnings Call Transcript
CDXC earnings call for the period ending December 31, 2020. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
From ChromaDex Corporation
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Acorda Therapeutics (NASDAQ:ACOR) stock moved upwards by 56.69% to $5.97 during Friday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
From ChromaDex Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.